United States - English - NLM (National Library of Medicine)

mylan institutional llc - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 3 mg in 1 ml - pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions h

United States - English - NLM (National Library of Medicine)

hospira, inc. - pamidronate disodium (unii: 8742t8zqza) (pamidronic acid - unii:oyy3447omc) - pamidronate disodium 6 mg in 1 ml - hypercalcemia of malignancy   pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 l/day throughout treatment. mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. diuretic therapy should not be employed prior to correction of hypovolemia. the safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. paget’s disease   pamidronate disodium is indicated for the treatment of patients with moderate to severe paget’s disease of bone. the effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. pamidronate disodium therapy in patients with paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with paget’s disease who failed to respond, or no longer responded to other treatments. osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. the pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see clinical pharmacology, osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma, clinical trials section). pamidronate disodium is contraindicated in patients with clinically significant hypersensitivity to pamidronate disodium or other bisphosphonates.

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - balsalazide disodium (unii: 1xl6bji034) (balsalazide - unii:p80al8j7zp) - balsalazide disodium 750 mg - balsalazide disodium capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. limitations of use: safety and effectiveness of balsalazide disodium capsules beyond 8 weeks in pediatric patients 5 years to 17 years of age and 12 weeks in adults have not been established. balsalazide disodium capsules are contraindicated in patients with known or suspected hypersensitivity to salicylates, aminosalicylates, or to any of the components of balsalazide disodium capsules or balsalazide metabolites [see warnings and precautions (5.3), adverse reactions ( 6.2), description ( 11)] . risk summary: published data from meta-analyses, cohort studies and case series on the use of mesalamine, the active moiety of balsalazide, during pregnancy have not reliably informed an association with mesalamine and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are adve

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

centre for advanced medicine - disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) - solution for injection - 150 mg/ml - active: disodium edetate 150 mg/ml (added as disodium edetate hydrous 166mg) excipient: hydrochloric acid sodium hydroxide water for injection

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pascoe's pty ltd - mono ethylene glycol; boron present as disodium octaborate tetrahydrate; benzalkonium chloride - liquid - mono ethylene glycol ungrouped active 878.0 g/l; boron present as disodium octaborate tetrahydrate mineral-boron active 52.0 g/l; benzalkonium chloride ammonium-quaternary active 12.0 g/l - mixed function pesticide - brick work | concrete | masonary | timber | brick structures | brick wall | bricks | painted concrete | path | paving | unpainte - algae | fungus | mould | termite | woodborer | anobiid | drywood termite | fungal leaf spots | fungi | fungus diseases | leaf spot diseases | leaf spots | lyctid | subterranean termite

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

us borax inc - boron present as disodium octaborate tetrahydrate - soluble powder - boron present as disodium octaborate tetrahydrate mineral-boron active 205.0 g/kg - mixed function pesticide - timber | wood - termite - excluding m. darwiniensis | woodborer | anobiid | lyctid

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

preschem pty. ltd. - boron present as disodium octaborate tetrahydrate; fluorine as sodium fluoride - slow release generator (inc. flea collars) - boron present as disodium octaborate tetrahydrate mineral-boron active 582.0 g/kg; fluorine as sodium fluoride mineral-fluorine active 243.0 g/kg - mixed function pesticide - timber - pole - brown rot | white rot

Australia - English - Department of Health (Therapeutic Goods Administration)

disodium edetate; sodium ascorbate -

Australia - English - Department of Health (Therapeutic Goods Administration)

disodium edetate; sodium ascorbate -